|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM186578474 |
| 003 |
DE-627 |
| 005 |
20231223174431.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.01.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0622.xml
|
| 035 |
|
|
|a (DE-627)NLM186578474
|
| 035 |
|
|
|a (NLM)19232508
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fevang, Børre
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.06.2009
|
| 500 |
|
|
|a Date Revised 18.05.2009
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Common variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by defective immunoglobulin production and high frequency of bacterial infections, autoimmunity and manifestations of chronic inflammation. The urokinase plasminogen activator (uPA), its cell bound and soluble receptor (uPAR, suPAR) have complex biological functions involving innate immune defense mechanisms and regulation of inflammation. Based on this dual role, we hypothesized that the uPA system could be affected in CVID, and examined expression of components of the uPA system in subgroups of CVID. All CVID-patients had increased plasma levels of suPAR with particularly high levels in those with splenomegaly and thrombocytopenia. Plasma uPA levels were also raised in these patients, and both suPAR and uPA levels correlated with the monocyte activation marker neopterin. Monocytes from CVID patients had increased expression of uPAR. We show an increased activation of the uPA system possibly contributing to the inflammatory phenotype seen in subgroups of CVID patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Receptors, Urokinase Plasminogen Activator
|2 NLM
|
| 650 |
|
7 |
|a Urokinase-Type Plasminogen Activator
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.73
|2 NLM
|
| 700 |
1 |
|
|a Eugen-Olsen, Jesper
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yndestad, Arne
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brosstad, Frank
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Beiske, Klaus
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aukrust, Pål
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Frøland, Stig S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 131(2009), 3 vom: 04. Juni, Seite 438-46
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:131
|g year:2009
|g number:3
|g day:04
|g month:06
|g pages:438-46
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.01.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 131
|j 2009
|e 3
|b 04
|c 06
|h 438-46
|